Mirum Pharmaceuticals vs Ultragenyx Pharmaceutical
MIRM and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MIRM and RARE compare
Mirum Pharmaceuticals is the larger company, worth 3.8 times as much as Ultragenyx Pharmaceutical ($6.1B against $1.6B).
Mirum Pharmaceuticals grew revenue faster over the last twelve months (44.0% versus 15.8% for Ultragenyx Pharmaceutical).
Ultragenyx Pharmaceutical keeps more of each dollar of sales as profit, with a net margin of −71.8% compared with −139% at Mirum Pharmaceuticals.
Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 5 for Mirum Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MIRM | RARE |
|---|---|---|
| Size and price | ||
| Market cap | $6.1B | $1.6B |
| Share price | $93.99 | $16.08 |
| Change, 1 year | 32.8% | −52.0% |
| Change, 5 years | 499% | −79.7% |
| Beta (5Y) | 0.63 | 1.07 |
| Employees | 372 | 1,371 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 1 | 1 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.9× | 2.2× (better) |
| FCF yield | −3.7% (better) | −27.9% |
| Growth | ||
| Revenue growth (TTM) | 44.0% (better) | 15.8% |
| Revenue growth, 5Y average | – | 19.9% |
| Profitability | ||
| Operating margin | −135% | −64.0% (better) |
| Net margin | −139% | −71.8% (better) |
| FCF margin | −37.0% (better) | −60.5% |
| Return on equity | −703% | – |
| Financial health | ||
| Interest coverage | −62.1× | – |
| Current ratio | 2.86 (better) | 1.40 |
| Altman Z-score | −0.14 (better) | −5.73 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 110% | 108% |
| Held by insiders | 9.2% | 4.0% |
| Insider net buying, 12 months | −$31.5M | −$3.8M (better) |
| Short interest, % of float | 11.1% | 25.0% |
Go deeper
- MIRM stock overview
- MIRM income statement
- MIRM valuation and score
- RARE stock overview
- RARE income statement
- RARE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.